SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
November, 2023
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes
¨ No
x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
| |
|
|
| Date: November 16, 2023 |
By: |
/s/ K Randhir Singh |
| |
|
Name: |
K Randhir Singh |
| |
|
Title: |
Company Secretary |
Exhibit 99.1
 |
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
November 16, 2023
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Press Release
Please find enclosed a Press Release on “Dr. Reddy's rolls out
Nerivio®, a USFDA-approved drug-free non-invasive migraine management device, in India”.
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer &
Head-CSR
Encl: As above
| |
CONTACT |
| DR. REDDY'S LABORATORIES LTD. |
Investor relationS |
Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, |
|
|
| Hyderabad - 500034. Telangana, India. |
RICHA PERIWAL |
USHA IYER |
| |
richaperiwal@drreddys.com |
ushaiyer@drreddys.com |
Dr.
Reddy's rolls out Nerivio®, a USFDA-approved drug-free non-invasive migraine management device, in India
| · | Nerivio® is the first and only USFDA approved
device to use Remote Electrical Neuromodulation (REN) to prevent and treat migraine |
| · | It is a drug-free wearable, and intended for
acute and prophylactic (preventive) migraine in patients aged 12 years and above |
| · | The device is accompanied by a user-friendly
app that comes with in-built features such as interactive migraine diary to log symptoms, track responses and share insightful analytics
|
| · | Additionally, the device is backed by Dr.
Reddy’s patient support programme for complete migraine care |
| · | Safe and well-tolerated with no systemic side-effects
or concern of overuse, unlike medication |
| · | Marks Dr. Reddy’s entry into digital
therapeutics as part of its innovative products business, having earlier ventured into e-commerce through ‘Celevida Wellness’,
and entered into collaborations with Jiangsu Hengrui & Junshi Lifesciences respectively to bring novel molecules such as pyrotinib
to India and toripalimab to India and select emerging markets |
Hyderabad India; November 16, 2023 –
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”),
a global pharmaceutical company, announced the roll-out of Nerivio® in India, a state-of-the-art United States Food and Drug Administration
(USFDA) approved wearable therapy device for drug-free management of migraine.
Migraine is a global health challenge, affecting
around 30% of adults on 15 or more days per month, impacting 1.7% to 4% of the population1. Migraines are known to have a
disproportionate impact on women, who constitute approximately 60% of the 213 million migraine sufferers in India alone2.
Nerivio® is a prescription-based non-invasive
device intended for acute and prophylactic (preventive) treatment of migraine with or without aura3 for adults and adolescents
aged 12 years and above. Nerivio® can be worn on the upper arm. Each device has in-built 18 x 45-minute treatment sessions. It is
to be used within 60 minutes of onset of headache for acute treatment of migraine or every alternate day for prevention of migraine.
The device uses the Remote Electrical Neuromodulation (REN) mechanism to specifically activate conditioned pain modulation by stimulating
nerve endings. This initiates a natural pain-relieving process in the brainstem, causing a global effect of pain inhibition that affects
the original source of migraine pain in the head4.
1 https://www.neurologyindia.com/article.asp?issn=0028-3886;year=2021;volume=69;issue=7;spage=4;epage=9;aulast=Krishnan
2 https://en.gaonconnection.com/india-migraine-stroke-2019-lancet-health-air-pollution-blood-pressure-headache-health-neurological-disorders/
3 Symptoms or sensations, such as flashing lights
or zigzag lines or loud sound, which typically precede migraine headache
4 https://nerivio.com/how-it-works/
M.V. Ramana, Chief Executive Officer, Branded Markets
(India and Emerging Markets), Dr. Reddy’s said, “The roll-out of Nerivio® marks our entry into digital
therapeutics (DTx). It is an area that is seeing increasing adoption by physicians as well as patients due to its potential to reduce
pill burden and decrease dependency on non-specific medication in chronic or hard-to-treat diseases. Given the migraine disease burden,
its associated symptoms, lack of effective treatment and impact on well-being, quality of life and productivity, we are happy to bring
Nerivio® to India. It is USFDA-approved, drug-free, non-invasive, first-of-its-kind product for migraine in India and offers
a favourable safety profile. We believe this product meets a genuine unmet clinical need among migraine patients. We look forward to receiving
patient and HCP feedback on it. While our core generics business continues to drive our current growth, Nerivio® as DTx joins our
e-commerce venture ‘Celevida Wellness’, and our recent deals to bring novel molecules such as toripalimab and pyrotinib to
India, as part of our innovative products initiatives in India aimed at improving patient well-being and outcomes.”
The unique device is accompanied by the Nerivio app,
which is user-friendly and freely available on Google Play Store and the Apple app store for download. The app can be used to control
the intensity levels of the device. It also has an interactive migraine diary which can be used to log symptoms, track responses and share
insightful analytics. The app also includes an interactive GIER (guided, imagery, education and relaxation) protocol which, if used with
Nerivio®, significantly increases the response rates.
As part of its patient support programme for Nerivio,
Dr. Reddy’s offers M-Free, a comprehensive support system that enhances and streamlines the journey of the patients. M-Free includes
services such as onboarding and counseling of patients, device demonstrations, doorstep delivery, flexible payment options, informative
content, and dedicated customer care to help patients get the most out of the device.
Clinically proven5 and safe, Nerivio®
is suitable for a wide range of patients, including those who prefer drug-free options, individuals with contraindications to medications
or poor medication tolerance, sensitive populations such as adolescents, women of vulnerable age groups and patients at risk of medication
overuse headache6. Studies show that Nerivio® is safe and well tolerated with no systemic side effects or concern for
medication overuse. It has been evaluated in robustly designed pivotal studies conducted in the U.S., in patients seeking effective acute
or preventive treatment of migraine. Nerivio® has proven efficacy in not only effectively treating relief of pain but also associated
symptoms in migraine such as nausea, vomiting etc. It has been shown to reduce the need for drugs used for acute treatment in nearly
9 out of 10 patients. Being an effective non-invasive therapy, the associated systemic adverse events are not a concern. This is extremely
useful in patients seeking preventive treatment of migraine since many patients experience tolerability issues with drugs, resulting
in significant impact on their quality of life, when used for long time (>3 months)7.
5 https://nerivio.com/
6 Babaei M, Rapoport AM. Expert Review of Medical
Devices. 2023 May 12:1-5.
7 Rapoport AM et al. 2020 Jan;60(1):229-34.
In January 2023, Dr. Reddy’s entered into an
exclusive agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine
and other pain conditions, for the marketing and distribution of Nerivio® in India. In August this year, Nerivio® received an
expanded CE mark approval under MDR European regulation as a dual-use (acute and/or prevention) migraine treatment for adults and adolescents.
Dr. Reddy’s also recently signed an exclusive agreement for the commercial marketing and distribution of Nerivio® in Germany,
Austria, Czech Republic, Denmark, Finland, France, Italy, Norway, Poland, Slovakia, Spain, Sweden, Switzerland and the United Kingdom8.
Nerivio® is a prescription-based product. Patients
are advised to consult their neurologists on the use of the device and management of migraine. For more queries, doctors and patients
can call the dedicated helpline number 1800-123-2360 (toll-free).
About Dr. Reddy’s:
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered
in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our
purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded
generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain
management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a
company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of
the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG
goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more
information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and
involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general
economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels
and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition
and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the
impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets
addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics
or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings
with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"
sections of our Annual Report on Form 20-F for the year ended March 31, 2023. The company assumes no obligation to update any information
contained herein.
8 CE mark: https://www.prnewswire.com/news-releases/nerivio-ce-mark-indication-expanded-to-preventive-and-acute-treatment-of-migraine-for-adolescents-and-adults-301896254.html
| Europe agreement: https://www.prnewswire.com/news-releases/theranica-enters-into-agreement-with-dr-reddys-for-commercializing-nerivio-in-europe-301986214.html
| India agreement: https://www.prnewswire.com/news-releases/theranica-enters-into-agreement-with-dr-reddys-for-commercializing-nerivio-in-india-301715697.html
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
